Saegis: Sae what?

Companies developing therapeutics for cognitive impairment have been hindered by the lack of a good animal model that mimics the disease process in humans. Saegis Pharmaceuticals Inc. believes it has found an approach to identify good targets and validate in-licensed compounds in preclinical models that will translate to success in developing drugs for Alzheimer's disease and a variety of other forms of cognitive impairment.

In November 2002,

Read the full 678 word article

How to gain access

Continue reading with a
two-week free trial.